Dupilumab, topical corticosteroids reduce itch in pediatric patients with AD

Source / Disclosures Published by:

Source:

Paller AS, et al. Dupilumab improves itching in children 6-11 years with severe atopic dermatitis: analysis of the LIBERTY AD PEDS study. Presented in: European Society for Pediatric Dermatology; May 12-14, 2021 (virtual meeting).

Disclosures:
Cork reports that he is a researcher and / or consultant to AbbVie, Astellas Pharma, Boots, Dermavant, Galapagos, Galderma, Hyphens Pharma, Johnson & Johnson, Leo Pharma, L’Oréal, Menlo Therapeutics, Novartis, Oxagen, Pfizer, Procter & Gamble, Reckitt Benckiser, Regeneron Pharmaceuticals, and Sanofi Genzyme. See the study for all relevant financial disclosures from other authors.

ADD SUBJECT TO EMAIL NOTIFICATIONS

Receive an email when new articles are posted

Enter your email address to receive an email when new articles are posted. “data-action =” subscribe “> Subscribe

We were unable to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Pediatric patients with atopic dermatitis treated with dupilumab and topical corticosteroids experienced an improvement in both itching and excoriation, according to a study presentation.

“Severe AD can be a significant burden for young children aged 6 to 11 and their families dealing with intense, unrelenting itching and skin lesions. The itchiness associated with severe AD can be debilitating and affect almost every aspect of these families’ lives, from sleep to school to play. If untreated, the cycle of itching and scratching can continue to damage the child’s skin, with progressive symptoms of cracking, bleeding, crusting and oozing, “researcher Michael J. Cork, BSc, MB, PhD, FRCP, chief of dermatology at Sheffield Dermatology Research and professor of dermatology at the University of Sheffield Medical School, Healio said.

The post-hoc analysis of the 16-week, double-blind, placebo-controlled phase 3 study in LIBERTY AD PEDS, presented at the virtual meeting of the European Society for Pediatric Dermatology, included patients 6 to 11 years of age with severe AD who were evaluated for change in itching intensity and frequency.

Of those who weighed less than 30 kg and received 300 mg of Dupixent (dupilumab, Regeneron) every 4 weeks in addition to topical corticosteroids, 54.1% had an improvement of at least 4 points in worst itch score on the numerical rating scale compared to 11.7 % of those who received topical corticosteroids only. In patients weighing more than 30 kg, 61.4% who received 200 mg dupilumab plus topical corticosteroids every 2 weeks had an improvement of 4 points or more, while 47.5% of those who received 300 mg dupilumab plus topical corticosteroids every 4 weeks and 12.9% of patients who received 300 mg dupilumab every 4 weeks. the corticosteroid-only group had the same improvement.

Itching intensity, as measured by SCORing Atopic Dermatitis itch Visual Analog Scale, decreased by 66.6% in the less than 30 kg group receiving 300 mg dupilumab every 4 weeks plus topical corticosteroids, compared to 8% in the corticosteroid only group . The over 30 kg group receiving 200 mg dupilumab every 2 weeks plus topical corticosteroids had a 73.1% reduction, while the 300 mg dupilumab every 4 weeks plus topical corticosteroids group had a 61.5% reduction and the corticosteroid only group had 26.2%. Reduce.

The study also found that after 16 weeks, more than half of the children treated with Dupixent plus topical corticosteroids (TCS) experienced a reduction in itching frequency from daily itching to up to 2 days per week, compared with only 13% to 16% with TCS alone, “Cork said.” The LIBERTY AD PEDS study found that Dupixent plus TCS significantly improved overall disease severity, skin clearance and itching in children 6 to 11 years of age with severe AD. hoc analysis showed that the clinically meaningful improvements in itching observed in the study were rapid and sustained, and that improvements were seen in both the intensity and frequency of itching. ”

ADD SUBJECT TO EMAIL NOTIFICATIONS

Receive an email when new articles are posted

Enter your email address to receive an email when new articles are posted. “data-action =” subscribe “> Subscribe

We were unable to process your request. Please try again later. If you continue to have this problem, please contact customerservice@slackinc.com.

Back to Healio

Comments are closed.